Division of Preventive Medicine and Public Health, University of Murcia School of Medicine, IMIB-Arrixaca, 30100 Espinardo, Murcia, Spain; Department of Preventive Medicine, General University Hospital "Reina Sofia", 30003 Murcia, Spain.
Department of Vascular and Interventional Radiology, General University Hospital "Reina Sofia", 30003 Murcia, Spain.
Diagn Interv Imaging. 2019 Mar;100(3):157-162. doi: 10.1016/j.diii.2018.08.013. Epub 2018 Sep 24.
The purpose of this study was to compare patency rates and risk of obstruction of catheter exchange (CE) with that of CE with fibrin sheath angioplasty (CE+FSA) in dysfunctional tunneled central hemodialysis venous catheter (CHVC).
A total of 107 consecutive patients with dysfunctional CHVC were retrospectively included. There were 66 men and 41 women with a mean age of 67.8±12.5 (SD) years (range: 23.0-86.0 years). Seventy-three of 107 patients (68.2%) underwent CE procedure and 34 of 107 (31.8%) underwent CE+FSA. Kaplan-Meier log-rank test and multivariate Cox regression analyses were performed to determine patency rates and risk of obstruction according to type of endovascular procedure.
Patency rates after endovascular procedures at 3, 6, 12, 24 and 36 months follow up were 75%, 75%, 65%, 65% and 65% in CE+FSA group and 70%, 65%, 62%, 30% and 0% in CE group. Mean time until obstruction of CHVC was 778.4 days after CE+FSA and 497 days after CE (P=0.211). Endovascular procedure was unrelated to risk of obstruction in adjusted model (HR=1.34; P=0.515).
Our findings suggest that both techniques are equivalent in terms of patency and safety results, so other aspects as cost assessment should be considered when choosing between both techniques.
本研究旨在比较功能障碍性隧道式中心血液透析静脉导管(CHVC)中导管交换(CE)与纤维鞘血管成形术(CE+FSA)的通畅率和阻塞风险。
回顾性纳入 107 例功能障碍性 CHVC 患者。其中男 66 例,女 41 例,平均年龄 67.8±12.5(SD)岁(范围:23.0-86.0 岁)。107 例患者中 73 例行 CE 治疗,34 例行 CE+FSA。采用 Kaplan-Meier 对数秩检验和多因素 Cox 回归分析,根据血管内治疗方式确定通畅率和阻塞风险。
CE+FSA 组和 CE 组血管内治疗后 3、6、12、24 和 36 个月的通畅率分别为 75%、75%、65%、65%和 65%和 70%、65%、62%、30%和 0%。CE+FSA 后 CHVC 阻塞的平均时间为 778.4 天,CE 后为 497 天(P=0.211)。调整模型中血管内治疗与阻塞风险无关(HR=1.34;P=0.515)。
我们的研究结果表明,两种技术在通畅率和安全性方面具有等效性,因此在选择两种技术时,应考虑其他方面,如成本评估。